This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): amphotericin b
Description: AmBisome is an antifungal agent that is administered by intravenous injection.It consists of amphotericin B encapsulated in a liposomal bilayer and acts by binding to the sterol component of the cell membrane, causing alterations in cell permeability and cell death.
Deal Structure: Gilead markets AmBisome in the major countries of Europe and co-promotes AmBisome in the U.S. with Fujisawa Healthcare, Inc. and established a marketing alliance with Sumitomo Pharmaceuticals.
In an agreement that began in 1995 with NeXstar Pharmaceuticals, Gilead and Fujisawa co-promote AmBisome in the United States for the treatment of life-threatening systemic fungal infections. Under the agreement, Fujisawa pays Gilead to manufacture the product, and Gilead receives approximately 20 percent of gross profits on U.S. sales.
Fujisawa has sole marketing rights to AmBisome in Canada. Sumitomo Pharmaceuticals maintains marketing rights to AmBisome in Japan. Gilead retains exclusive marketing rights to AmBisome in the rest of the world.
In an agreement that began in 1996 with NeXstar Pharmaceuticals, Sumitomo has the rights to develop and market AmBisome in Japan. Under this agreement, Sumitomo will pay development and clinical trial costs in Japan, as well as clinical and...See full deal structure in Biomedtracker
Partners: Gilead Sciences, Inc. Sumitomo Dainippon Pharma Co., Ltd. Mylan Inc.
Pink Sheet In Brief: Nexstar/Fujisawa AmBisome
Additional information available to subscribers only: